team contact us vaccine research & development neurologicalbiomarkers neurologicaltherapies welcome to jn international medical corporation a u.s. based private biopharmaceutical corporation has been developing vaccines for infectious disease and neurological disorders . emphasis on our 20 years of basic research combined with an applied focus on specific medical needs was instrumental to success and growth of this corporation . as vaccine research and development took exciting new directions through emerging knowledge about cure unknown diseases jn continued to press forward . even as many others abandoned vaccine research jn remained on the leading edge in vaccine development . in fact jn has played a leading role in the inventing of some of the most signi cant vaccine advances over the last two decades and our commitment and excitement about vaccines today are stronger than ever . scientific discovery contact us name e mail phone date the corporation do you know jn is the 3rd biopharma to develop patented meningococcal meningitis serogroups a c y w135 diphtheria toxoid conjugate vaccine nmvac 4dt . promising new studies attempt to perfect genital herpes and meningitis serogroup b vaccines . inc 5000 fastest growing company . read more meningococcal meningitis what special of this vaccine nmvac 4 a c y w 135 dt conjugate vaccine is among the most complex biotech or biologic products . it s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup a c y & w 135 and it is suitable for all ages . the only true halal vaccine nmvac 4 a c y w 135 dt conjugate vaccine is made with 100 % vegetable media with no animal components used in upstream and downstream process . the process and media have been patented . the vaccine is suitable for millions of muslims worldwide and other religions . most importantly the vaccine is free from bovine spongiform encephalopathy bse commonly known as mad cow disease . read more news & events april 2015 immunogenicity and safety of jn s serogroups a c y & w 135 meningococcal polysaccharide diphtheria toxoid conjugate vaccine nmvac 4 a c y w135 dt results published clinical trials.govread more ... april 2015 immunogenicity and safety of jn s serogroups a c y & w 135 meningococcal polysaccharide diphtheria toxoid conjugate vaccine nmvac 4 a c y w135 dt planned to conduct in 20 centers in the united states by irc clinics in maryland read more ... vaccine research & development stroke therapeutic genital herpes meningococcal serogroup b hepatitis c patents & publications 2012 meningitis vaccine for all ages stroke therapeutic huntington s therapeutic neurological biomarkers alzheimer s transient ischemic attack stroke parkinson s huntington s journal articles 2014 quantification of neisseria meningitidis in a c y w 135 dt conjugate vaccine determining trace amounts and the origin of formaldehyde impurity quick links about us research & development news & events patents & publications testimonials jni has strictly controlled and fully equipped class 100 to 100 000 rooms to carry out manufacturing operations . which are fully validated and controlled in all quality cgmp aspects . the facility has qc labs classified as bio safety level 2 . follow us contact us mobile 14025162102 peter jn vaccines.org 2720 north 84th street . omaha ne 68134 usa . copyright 2014 jn international medical corporation . all rights reserved . bylaws terms of use legal disclaimer